All the news Showing 3 of 33 articles from: CirrhosisGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Triple-drug HCV therapy comes with high risk of serious adverse events for people with cirrhosis Keith Alcorn / 30 April 2013 Currently available triple therapies for hepatitis C carry a high risk of serious side-effects for people in the most urgent need of treatment, and these patients have only a moderate chance of being ... Decompensated liver disease more frequent in HIV/HCV co-infected people Liz Highleyman / 26 July 2012 Despite effective antiretroviral therapy, people co-infected with HIV and hepatitis C remain at higher risk for decompensated liver disease and other liver-related complications than those with hepatitis C alone, according to findings presented on ... BI 201335 & BI 207127 and ribavirin shows good efficacy, including hepatitis C patients with cirrhosis Liz Highleyman / 15 May 2012 An interferon-free regimen of the hepatitis C virus (HCV) protease inhibitor BI 201335, the non-nucleoside polymerase inhibitor BI 207127, and ribavirin produced sustained virological response in 68% of previously untreated genotype 1 hepatitis C ... ← Prev1234Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive